Ashkan Shoamanesh: Factor XI Inhibition and the Future of Antithrombotic Therapy
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn about a recent article he and his colleagues co-authored, published in NEJM Group, adding:
”The OCEANIC-STROKE results published in NEJM Group last week advance the promise of factor XI/XIa inhibition as a new paradigm in antithrombotic therapy.
In discussion with HCP Live Cardiology, we explore what these findings mean for patients with non-cardioembolic stroke or high-risk TIA – particularly asundexian’s ability to reduce ischemic stroke risk without increasing bleeding.
Beyond stroke, FXI inhibition may have broader implications across cardiovascular disease, where the balance between thrombosis and bleeding has long constrained progress.
Very grateful to contribute to this evolving chapter in secondary prevention alongside my colleagues.”
Title: Asundexian for Secondary Stroke Prevention
Authors: Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott Kasner, Jeffrey Saver, Jaime Masjuan, Andrew Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov, Hee-Joon Bae, Bruce Campbell, Andrea Zini, I-Hui Lee, Martin Kovar, Robert Mikulik, Robin Lemmens, José Ferro, Thompson Robinson, Hanne Christensen, Serefnur Ozturk, Ronen Leker, Peter Turcani, Agnieszka Slowik, Pablo Amaya, Fan Kee Hoo, Gian Marco De Marchis, Michael Knoflach, P.N. Sylaja, Jukka Putaala, Jonathan Coutinho, H. Bart van der Worp, Evija Miglane, Vaidas Matijošaitis, Arne Lindgren, Gisele Sampaio Silva, Else Charlotte Sandset, Saule Turuspekova, Pierre Amarenco, Kevin Sheth, Eric Smith, John Eikelboom, Raed Joundi, Karleen Schulze, Lizhen Xu, Laura Heenan, Pablo Colorado, Lars Keller, Eva Muehlhofer, Christoph Neumann, Hardi Mundl, Ashkan Shoamanesh for the OCEANIC-STROKE Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 25, 2026, 18:36James P. Crowley: Gene Inactivation and Targeted Gene Repair as Two Approaches to CRISPR Gene Editing
-
Oct 25, 2026, 17:43Jan Sloves: Femoral Vein Aneurysm and Chronic Venous Obstruction
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna Riley։ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care